ListarGI-FENM - Artigos por tema "Pegvisomant"

Mostrando ítems 1-2 de 2

    • Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain 

      Peral, Carmen; Cordido, Fernando; Gimeno-Ballester, Vicente; Mir, Nuria; Sánchez-Cenizo, Laura; Rubio-Rodríguez, Darío; Rubio-Terrés, Carlos (Taylor&Francis, 2020-05-06)
      [Abstract] Objective: To estimate the cost-effectiveness of second-line pharmacological treatments in patients with acromegaly resistant to first-generation somatostatin analogues (FG SSA) from the Spanish National ...

    • Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: the ACROCOMB study 

      Puig-Domingo, Manuel; Soto, Alfonso; Venegas, Eva; Vílchez, Ricardo; Blanco, Concepción; Cordido, Fernando; Lucas, Tomás; Marazuela, Mónica; Casany, Rosa; Cuatrecasas, Guillem; Fajardo, Carmen; Gálvez, María Ángeles; Maraver, Silvia; Martín, Tomás; Romero, Enrique; Paja, Miguel; Picó, Antonio; Bernabéu, Ignacio; Resmini, Eugenia (Elsevier, 2016-11-04)
      [Abstract] PURPOSE: To describe real-world use of lanreotide combination therapy for acromegaly. PATIENTS AND METHODS: ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated ...